Rybrevant’s Second Act: How J&J Is Rewriting the Rules for EGFR-Mutant Lung Cancer
From exon 20 insertions to subcutaneous delivery and inclusive trial design, Joshua Bauml explains why the biology demanded a...
Women’s Hearts, Underserved by Design: Anteris Technologies President David St. Denis on Closing Structural Heart’s Most Overlooked Gap
The problem isn't that fewer women get aortic stenosis. It's that the entire pipeline, from diagnosis to device, was...
When the ER Is Not an Option: Milestone’s CMO on Bringing AFib Rate Control Home
The FDA approval of etripamil for PSVT occurred in December, 2025. Investigation about a potential role of etripamil in...
The Data Integrity Crisis That Built a Company: Rick Graham on Why Clinical Trials Keep Failing Before the AI Even Starts
TruTechnologies co-founder Rick Graham argues that the industry's real execution problem is not a modeling problem.
Asia Pacific Is No Longer a Backup Plan. Sponsors Who Still Treat It That Way Are Falling Behind.
Precision for Medicine's James Cheong and JingPing Yeo on what has actually changed in APAC clinical operations, and what...
When the CRO and Sponsor Speak the Same Language, Oversight Stops Being a Negotiation
Ed Fowler, Parexel's former Vice President of Operational Excellence, on what shared CTMS infrastructure has changed — and what...
The FDA Alignment Playbook Behind Ocular Therapeutix’s Single-Trial NDA
How Ocular engineered a retinal drug program backward from approval, and what that means for every sponsor still designing...
Pediatric Dermatology’s Blind Spot: How Arcutis Built a Drug Pipeline Where the Industry Wouldn’t Look
Frank Watanabe turned a clinician's frustration into a regulatory strategy that has now yielded seven approvals for ZORYVE. The...
Veeva’s eSource Isn’t Another Digital Layer. It’s the Last One.
Manny Vazquez and Denali Rose on why the industry's oldest data-entry problem is finally solvable and why sites have...
When Privacy Is the Product: How Albus Health Is Redefining What Clinical Trials Can Measure at Home
A contactless device, 40 countries, and a design philosophy that starts with patients — not compliance checklists The question...